What is the initial dose of Lantus (insulin glargine) for an adult patient with poorly controlled diabetes and hyperglycemia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 2, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Initial Lantus Dosing for Severe Hyperglycemia

For a patient with A1C 12.9% and blood glucose 305 mg/dL, start Lantus at 0.3-0.5 units/kg/day as part of an immediate basal-bolus insulin regimen, not basal insulin alone. 1

Why Basal-Bolus from the Start

This degree of hyperglycemia (A1C ≥10%, glucose ≥300 mg/dL) warrants both basal and prandial insulin coverage immediately rather than starting with basal insulin alone. 1, 2 At this A1C level, basal insulin monotherapy will be insufficient—you need to address both fasting and postprandial hyperglycemia from day one. 1

Specific Dosing Algorithm

Calculate total daily insulin dose:

  • Use 0.3-0.5 units/kg/day as your starting point for severe hyperglycemia 1, 2
  • For a 70 kg patient: 21-35 units total daily dose
  • For a 90 kg patient: 27-45 units total daily dose

Split the dose 50:50:

  • Give 50% as Lantus once daily (bedtime or morning) 1, 2
  • Give 50% as rapid-acting insulin divided among three meals 1, 2

Example for 80 kg patient:

  • Total daily dose: 24-40 units (using 0.3-0.5 units/kg)
  • Lantus: 12-20 units once daily
  • Rapid-acting insulin: 4-7 units before each meal

Titration Protocol

Basal insulin adjustment:

  • Increase Lantus by 4 units every 3 days if fasting glucose ≥180 mg/dL 1
  • Increase by 2 units every 3 days if fasting glucose 140-179 mg/dL 1
  • Target fasting glucose: 80-130 mg/dL 1

Prandial insulin adjustment:

  • Increase each meal dose by 1-2 units every 3 days based on 2-hour postprandial glucose 1
  • Target postprandial glucose: <180 mg/dL 1

Critical Threshold to Monitor

Watch for overbasalization when Lantus exceeds 0.5 units/kg/day (36 units for 70 kg patient). 1 At this point, add or intensify prandial insulin rather than continuing to escalate basal insulin. 1 Clinical signals include:

  • Basal dose >0.5 units/kg/day
  • Bedtime-to-morning glucose drop ≥50 mg/dL
  • Hypoglycemia episodes
  • High glucose variability 1

Essential Concurrent Therapy

Continue metformin at maximum tolerated dose (up to 2000-2500 mg daily) unless contraindicated. 1, 2 This combination provides superior glycemic control with reduced insulin requirements and less weight gain compared to insulin alone. 1, 2

Discontinue sulfonylureas when implementing basal-bolus insulin to prevent severe hypoglycemia. 1, 2

Expected Outcomes

With appropriate basal-bolus therapy at weight-based dosing, expect A1C reduction of 2-3% from current levels. 2 With proper implementation, 68% of patients achieve mean blood glucose <140 mg/dL. 2

Common Pitfalls to Avoid

Never start with basal insulin alone at this A1C level. Blood glucose of 305 mg/dL with A1C 12.9% reflects both inadequate basal coverage AND postprandial excursions requiring mealtime insulin from the outset. 1

Never rely on sliding scale insulin as monotherapy. This approach is explicitly condemned by all major diabetes guidelines and treats hyperglycemia reactively rather than preventing it. 1, 2

Never delay insulin intensification. Prolonged severe hyperglycemia (months at A1C >9%) significantly increases complication risk. 2

Monitoring Requirements

  • Check fasting blood glucose daily during titration 1
  • Check pre-meal and 2-hour postprandial glucose to guide prandial insulin adjustments 1
  • Reassess every 3 days during active titration 1
  • Check A1C every 3 months during intensive titration 1

Patient Education Essentials

  • Proper insulin injection technique and site rotation 1
  • Recognition and treatment of hypoglycemia (treat glucose <70 mg/dL with 15 grams fast-acting carbohydrate) 1
  • Self-monitoring of blood glucose 1
  • Timing: rapid-acting insulin 0-15 minutes before meals 1

References

Guideline

Initial Dosing for Lantus (Insulin Glargine) in Patients Requiring Insulin Therapy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Insulin Intensification for Patients with Elevated A1c

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

What is the recommended increment for Lantus (insulin glargine) dosage?
What is the comparison between 70/30 (pre-mixed insulin) and Glargine (insulin glargine) in terms of indications, price, availability, and effectiveness for diabetes management?
What adjustments should be made to the Lantus (insulin glargine) dose, carb ratio, and correction scale for an 84-year-old type 2 diabetes patient with elevated overnight blood glucose levels?
What would be the NPO (nothing by mouth) dose of Lantus (insulin glargine) for a 65-year-old male with type 2 diabetes taking 15 units daily?
What should the Lantus (insulin glargine) dose be for a patient with type 1 diabetes who has undergone a pancreas transplant and is currently NPO (nothing by mouth)?
What are the guidelines for administering Total Parenteral Nutrition (TPN) to a patient with severe gastrointestinal disease or post-surgical complications over a 24-hour period?
What medication could worsen liver function in an alcoholic patient with hepatocholestatic pattern?
What is the best course of action for a 62-year-old female with a history of Multiple Sclerosis (MS) who was diagnosed with COVID-19 3 days ago, is experiencing anxiety and tingling in her hands and feet, and is currently being treated with Zofran (ondansetron) for nausea, but has stable vital signs and no respiratory symptoms?
What are the potential side effects of Humira (adalimumab)?
What workup is recommended for an obese patient with elevated liver enzymes, specifically AST and ALT, and a weight of 320 pounds?
Is mirtazepine (Remeron) contraindicated in a patient with bipolar disorder and Attention Deficit Hyperactivity Disorder (ADHD)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.